Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy
Information source: Emory University
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Urolithiasis
Phase: N/A
Status: Recruiting
Sponsored by: Emory University Official(s) and/or principal investigator(s):
Kenneth Ogan, MD, Principal Investigator, Affiliation: Emory University
Overall contact:
Kenneth Ogan, MD, Phone: 404-778-3038, Email: kenneth_ogan@emoryhealthcare.org
Summary
The majority of kidney stones are treated with shock wave lithotripsy (SWL). We are
examining if the medication Flomax will result in improved stone passage rates following
SWL.
Clinical Details
Official title: Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy
Study design: Longitudinal, Defined Population, Prospective Study
Detailed description:
Placebo blinded study examining the effects of Flomax on stone passage rates following SWL.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- urolithiasis undergoing SWL
Locations and Contacts
Kenneth Ogan, MD, Phone: 404-778-3038, Email: kenneth_ogan@emoryhealthcare.org
Emory University, Atlanta, Georgia 30322, United States; Recruiting
Kenneth Ogan, MD, Phone: 404-778-3038, Email: kenneth_ogan@emoryhealthcare.org
Additional Information
Starting date: April 2005
Ending date: September 2005
Last updated: February 7, 2006
|
